Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Micombi Can Be Differentiated from Other Combination Drugs: Mr Imahori of Astellas
July 20, 2009
- Fuji Keizai Predicts 4% Increase in OTC Anti-Obesity Drugs in 2009
July 20, 2009
- Higher Dosage Approved for Cravit: Daiichi Sankyo
July 20, 2009
- Sales of Class 1 OTC Drugs Down due to New Marketing System
July 20, 2009
- New Class 1 OTC Drugs Get Off to Flying Start: Taisho
July 20, 2009
- R&D NEWS IN BRIEF
July 20, 2009
- Japan Biotechnology Conference Kicked Off by 20 Biotech Firms
July 20, 2009
- ASCO 2009 Highlight Seminar by the Matson Jack Group
July 20, 2009
- Pfizer Discontinues PIII Trial of Sutent in Metastatic CRC
July 20, 2009
- GENERICS NEWS IN BRIEF
July 20, 2009
- Survey on Generics of Anticancer Drugs Shows Gaps between Generic Firms and Healthcare Professionals
July 20, 2009
- Anplag to Be Major Target for Generic NHI Price Listing in November
July 20, 2009
- REGULATORY NEWS IN BRIEF
July 20, 2009
- Nissui Pharma. to Market Switch OTC Version of Epadel from Mochida
July 13, 2009
- JSGM Presents Proposals to Promote Use of Generics
July 13, 2009
- Korosho to Inspect Generics Containing 5 More APIs
July 13, 2009
- Lasting Decreases in BP Obtained with Telmisartan + Amlodipine
July 13, 2009
- Concrete Reasons for Lack of Enthusiasm about Use of Generics to Be Determined
July 13, 2009
- R&D NEWS IN BRIEF
July 13, 2009
- Biosimilars Will also Struggle in Japan: Datamonitor
July 13, 2009
ページ
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…